Skip to main content

Advertisement

Table 1 Demographic and Clinical Characteristics

From: Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q™), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women

Item Enrolled (N = 104)
Age (years) mean (SD) 65.1 (10.3)
Race n (%)  
   White 67 (64.4%)
   Black 1 (1.0%)
   Hispanic 36 (34.6%)
Living Situation  
   Living alone 25 (24.0%)
   Living with another 77 (74.0%)
   Other 2 (1.9%)
Work Status  
   Full-time 17 (16.3%)
   Part-time 19 (18.3%)
   Currently not working at a paid job 61 (58.7%)
   Other 7 (6.7%)
Education (highest level completed)  
   Elementary 4 (3.8%)
   High school 38 (36.5%)
   Some college 31 (29.8%)
   College degree 19 (18.3%)
   Postgraduate 10 (9.6%)
   Other 2 (1.9%)
Time since diagnosis (years), mean ± SD 6.4 ± 7.0
No Health Insurance 16 (15.4%)
Time since first starting prescription meds for osteoporosis (bisphosphonates)  
   < 3 months ago 7 (6.7%)
   > 3 months – 1 year 14 (13.5%)
   > 1 – 3 years ago 35 (33.7%)
   > 3 years 48 (46.2%)
Current Osteoporosis Treatment 1  
   Weekly alendronate 61 (59%)
   Daily alendronate 13 (13%)
   Weekly risendronate 21 (20%)
   Daily risendronate 6 (6%)
Experienced at least 1 fracture since menopause n (%) 27 (26.0%)
Comorbid conditions n (%)  
   Angina 3 (2.9%)
   Arthritis 59 (56.7%)
   COPD 6 (5.8%)
   Congestive heart failure 3 (2.9%)
   Depression 17 (16.3%)
   Hypertension 32 (30.8%)
   Other 26 (25.0%)
  1. 1Missing medication data for 1 subject; missing medication frequency data for 2 risedronate subjects.